REVELATION BIOSCIENCES INC (REVB) Stock Price, Quote, News and Overview
NASDAQ:REVB - Nasdaq - US76135L5075 - Common Stock - Currency: USD
REVB Quote, Performance and Key Statistics
4.31
-0.09 (-2.05%)
The current stock price of REVB is 4.31 USD. In the past month the price decreased by -16.47%. In the past year, price decreased by -90.38%.
REVB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About REVB
Company Profile
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2020-10-08. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
Company Info
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA US
Employees: 9
Company Website: https://www.revbiosciences.com/
Phone: 16508003717
REVELATION BIOSCIENCES INC / REVB FAQ
What is the stock price of REVELATION BIOSCIENCES INC today?
The current stock price of REVB is 4.31 USD. The price decreased by -2.05% in the last trading session.
What is the ticker symbol for REVELATION BIOSCIENCES INC stock?
The exchange symbol of REVELATION BIOSCIENCES INC is REVB and it is listed on the Nasdaq exchange.
On which exchange is REVB stock listed?
REVB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REVELATION BIOSCIENCES INC stock?
7 analysts have analysed REVB and the average price target is 174.14 USD. This implies a price increase of 3940.35% is expected in the next year compared to the current price of 4.31. Check the REVELATION BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REVELATION BIOSCIENCES INC worth?
REVELATION BIOSCIENCES INC (REVB) has a market capitalization of 2.24M USD. This makes REVB a Nano Cap stock.
How many employees does REVELATION BIOSCIENCES INC have?
REVELATION BIOSCIENCES INC (REVB) currently has 9 employees.
What are the support and resistance levels for REVELATION BIOSCIENCES INC (REVB) stock?
REVELATION BIOSCIENCES INC (REVB) has a support level at 3.99 and a resistance level at 4.43. Check the full technical report for a detailed analysis of REVB support and resistance levels.
Should I buy REVELATION BIOSCIENCES INC (REVB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of REVB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of REVB, evaluating the profitability, health, valuation and growth aspects
- REVELATION BIOSCIENCES INC (REVB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REVELATION BIOSCIENCES INC (REVB) Sales and EPS estimates to see what analysts future expectations are.
- REVELATION BIOSCIENCES INC (REVB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REVELATION BIOSCIENCES INC (REVB) Insider and Institutional Ownership to learn about the owners and their transactions.
- REVELATION BIOSCIENCES INC (REVB) Stock Chart to make your own analysis
- REVELATION BIOSCIENCES INC (REVB) Latest news and press-releases to stay up to date.
Does REVELATION BIOSCIENCES INC (REVB) stock pay dividends?
REVB does not pay a dividend.
When does REVELATION BIOSCIENCES INC (REVB) report earnings?
REVELATION BIOSCIENCES INC (REVB) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of REVELATION BIOSCIENCES INC (REVB)?
REVELATION BIOSCIENCES INC (REVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-143.21).
REVB Technical Analysis
REVB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to REVB. REVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
REVB Financial Highlights
Over the last trailing twelve months REVB reported a non-GAAP Earnings per Share(EPS) of -143.21. The EPS decreased by -1463.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -230.2% | ||
| ROE | -580.33% | ||
| Debt/Equity | 0 |
REVB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to REVB. The Buy consensus is the average rating of analysts ratings from 7 analysts.